Skip to content

Metastatic prostate cancer: does surgery still have a role?

Few or many metastases, standard treatment, prostate radiotherapy and what is known about surgery.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 19, 2026
Book a consultation
Drawing of the pelvic skeleton seen from the front, with the lowest vertebrae of the spine, the sacrum, the hip bones and the top of the thigh bones, and the bladder and prostate in the middle. The prostate has a purple tumor, and three purple spots with a light halo appear in the bone, in a vertebra, in the hip bone and in the thigh bone.
On this page

Quick answer

When prostate cancer has already spread at diagnosis, standard treatment in the 2026 European guideline is hormone therapy combined with a second drug, and the guideline recommends not offering castration alone to men who are fit for the combination. When there are only a few metastases (low volume by the CHAARTED criteria), the guideline recommends adding radiotherapy to the prostate.1 Surgery to the prostate at this stage, cytoreductive prostatectomy, still has no results from a large randomized trial, and the guideline recommends not offering it outside clinical trials.1 In my view, the benefit of surgery when there are only a few metastases is still debated, and the decision is made case by case, discussed with the patient.

What changes when there are metastases

A metastasis is cancer that has left the prostate and reached other parts of the body, such as the bones, lymph nodes far from the pelvis or organs such as the liver and lungs.1

When the cancer has already spread at diagnosis, treatment becomes treatment of the whole body, with medication. Treating the prostate itself becomes a separate question: does it help someone who already has disease outside it? That is the question this page looks at.

Suspicious lymph nodes confined to the pelvis (cN1) are a different situation and do not count as distant metastasis: in the 2026 European guideline table, they are classed as locally advanced cancer.2 In that case, I operate, with extended removal of the lymph nodes.

Few or many metastases

Metastatic cancer varies a great deal. The European guideline notes that survival in men who present with metastases can vary with the number and location of bone metastases, organ metastases, ISUP grade group, PSA and general health.1 Two trials created the yardsticks most often used to separate cases:1

YardstickHighLow
Volume (CHAARTED)Organ metastases, or 4 or more bone metastases with at least one outside the spine and pelvisAnyone without high volume
Risk (LATITUDE)At least two of: ISUP 4 or 5, 3 or more bone metastases, organ metastasesAnyone without high risk

Lymph nodes do not count as organ metastases in these yardsticks.1

"Oligometastatic" means few metastases, but there is no single number. The definition changes a lot with the scan used.1 The surgery studies, for example, accepted up to 3 bone lesions or up to 5 metastases, always without organ metastases.10,13

The role of PSMA PET

The European guideline recommendations for metastatic disease were based on conventional imaging: bone scan and CT or MRI.1 PSMA PET sees much smaller lesions. So a man with one or two lesions seen only on PSMA PET is not the same kind of patient as those in the trials that created these yardsticks, and that matters when choosing treatment.

Standard treatment in the European guideline

The backbone of treatment is hormone therapy, which lowers testosterone. Over the past decade, trials have shown that adding a second drug from the start improves survival:

  • CHAARTED: 790 men. Adding docetaxel to hormone therapy increased median survival from 44.0 to 57.6 months.3 The benefit was clearest in men with high-volume disease.1
  • LATITUDE: 1,199 men with high-risk metastatic cancer. Adding abiraterone reduced the risk of death by 38%.4 At 3 years, 66% were alive with abiraterone and 49% without it.1

In the 2026 European guideline, for men who present with metastases:1

RecommendationStrength
Discuss every case in a multidisciplinary teamStrong
Do not offer castration alone to men fit for combination treatment with a life expectancy of at least 1 yearStrong
Castration with abiraterone, apalutamide, enzalutamide or rezvilutamideStrong
Castration with darolutamideWeak
Docetaxel only together with castration and abiraterone or darolutamideStrong
Test for DNA repair gene changes, such as BRCA, because they may allow another drug to be added to abirateroneWeak

The choice of drug depends on side effects, other medical conditions and the volume of disease. The hormone therapy page explains the side effects and how to reduce them.

Prostate radiotherapy in low-volume disease

Treating the prostate when metastases are already present was first tested with radiotherapy:

  • STAMPEDE: 2,061 men. Prostate radiotherapy did not improve survival in the whole group.5 In the 819 men with low-volume disease, it did: with long-term follow-up, the risk of death fell by 36%, with no difference in high-volume disease.5,6
  • STOPCAP: the pooled analysis of the trials, with 2,126 men, showed 7% more men alive at 3 years with radiotherapy among those with fewer than 5 bone metastases.7
  • PEACE-1: 1,172 men. In low-volume disease treated with abiraterone, prostate radiotherapy delayed progression on scans from 4.4 to 7.5 years, without changing survival.8 It also reduced serious urinary complications such as obstruction and bleeding.1,8

As a result, the European guideline recommends offering prostate radiotherapy, together with hormone therapy, to men who present with low-volume metastatic disease by the CHAARTED criteria (strong recommendation).1

What about surgery? What the studies show

Cytoreductive prostatectomy is removal of the prostate when the cancer has already spread. The idea is similar to radiotherapy: treat the prostate tumor and prevent local problems it can cause, such as urinary obstruction and bleeding.10,11 These are the studies published so far:

StudyDesignWhat it showed
Culp, 2014US database with 8,185 men with metastases, 245 of them operated onMen who had surgery lived longer, but the study was not randomized, and the database had no information on the drugs they received9
Heidenreich, 201523 men with up to 3 bone lesions and a good response to hormone therapy, compared with 38 treated without surgeryLonger time to castration resistance (40 vs 29 months), with no difference in overall survival10
LoMP, 202280 men in Belgium, 40 operated on and 40 without surgery, not randomizedMen who had surgery were younger and had fewer metastases. After adjusting for this, surgery did not change the time to castration resistance. Complications were similar to surgery without metastases11
TRoMbone, 202251 men randomized in the UK, to test whether a larger trial was possibleRandomization was possible, and surgery was safe, with no major impact on quality of life and early functional results similar to standard surgery12
Dai, 2022200 men with up to 5 metastases randomized at one center in Shanghai: hormone therapy alone or with treatment of the prostate (85 operations and 11 radiotherapy courses)With treatment of the prostate, 88% were alive at 3 years, compared with 70% without13

The Shanghai trial showed a survival gain with randomization, but it is a phase 2 trial from a single center, and the comparison group received hormone therapy alone, which is no longer standard treatment.1,13 Larger randomized trials are under way. SWOG S1802, in the United States, compares drug treatment with and without treatment of the prostate, by surgery or radiotherapy, and g-RAMPP, in Germany, with and without prostatectomy.14 So far, they have not published their results.

What the European guideline says

The 2026 European guideline recommends not offering surgery, together with hormone therapy, to men with metastases outside clinical trials (strong recommendation).1 It also recommends treating the metastases themselves, with radiotherapy or surgery to each lesion, only within clinical trials or well-designed studies (strong recommendation).1

In short, the guideline separates the two ways of treating the prostate in metastatic disease. Radiotherapy, in low-volume disease, has large trials in its favor and is recommended. Surgery is still waiting for the randomized trials.

How I approach it

At the consultation, I review the biopsy, PSA and imaging, including PSMA PET, and explain which situation your case is in: distant metastases, lymph nodes only in the pelvis, or cancer confined to the prostate. That answer changes the whole path.

In my view, the benefit of surgery when there are only a few metastases is still debated. The decision is made case by case, discussed with you, looking at your scans and at what the studies show so far. When there are suspicious lymph nodes only in the pelvis (cN1), I operate, with extended removal of the lymph nodes, as I explain on the locally advanced cancer page.

I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. The pages on high-risk cancer and whether prostate cancer is curable help with the other scenarios. A second opinion can be done entirely online, in English, with your test results sent in advance.

Send your case

If you have been diagnosed with metastatic prostate cancer and would like my opinion before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is oligometastatic prostate cancer?

It is cancer that has already spread to other parts of the body, but to only a few places. There is no single definition, and the number of metastases that fits the term depends heavily on the scan used to look for them.1 Studies have used different limits, such as up to 3 bone lesions or up to 5 metastases, with no metastases in organs such as the liver or lungs.10,13

What is the difference between high-volume and low-volume metastatic prostate cancer?

By the CHAARTED criteria, high volume means metastases in an organ (such as the liver or lungs) or 4 or more bone metastases with at least one outside the spine and pelvis. Anything else is low volume. Lymph nodes do not count as organ metastases.1,3 The LATITUDE trial used a different yardstick, high risk, defined as at least two of three features (ISUP grade group 4 or 5, 3 or more bone metastases and organ metastases).1,4

What is the standard treatment for metastatic prostate cancer?

In the 2026 European guideline, the backbone is hormone therapy (castration) combined with a second drug, such as abiraterone, apalutamide, enzalutamide or darolutamide. Castration alone should not be offered to men who are fit for the combination. Docetaxel is used only together with castration and abiraterone or darolutamide, and every case should be discussed by a multidisciplinary team.1

Does radiotherapy to the prostate help when there are already metastases?

In low-volume disease, yes. In STAMPEDE, prostate radiotherapy did not improve survival in the whole group, but it did in men with low-volume disease.5,6 The European guideline recommends offering prostate radiotherapy, together with hormone therapy, to men who present with low-volume metastatic disease by the CHAARTED criteria (strong recommendation).1

Can the prostate be removed when the cancer has already spread?

Surgery in this setting is called cytoreductive prostatectomy. Most of the available studies are case series and small trials, and the large randomized trials have not yet published their results.9,10,11,12,13,14 The European guideline recommends not offering surgery to men with metastases outside clinical trials (strong recommendation).1 In my practice, the benefit of surgery when there are only a few metastases is still debated, and the decision is made case by case, discussed with the patient.

Is cancer in the pelvic lymph nodes only considered metastatic?

No. Suspicious lymph nodes confined to the pelvis (cN1) are classed as locally advanced cancer in the 2026 European guideline, not as distant metastasis.2 In that situation, I operate, with extended removal of the lymph nodes.

Does PSMA PET change this classification?

It can. The European guideline recommendations for metastatic disease were based on bone scans and CT or MRI. PSMA PET picks up smaller lesions, and the definition of few metastases depends heavily on the scan used.1

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
  3. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746. PubMed
  4. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360. PubMed
  5. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-2366. PubMed
  6. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998. PubMed
  7. Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019;76(1):115-124. PubMed
  8. Bossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2024;404(10467):2065-2076. PubMed
  9. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058-1066. PubMed
  10. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832-838. PubMed
  11. Buelens S, Poelaert F, Claeys T, et al. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int. 2022;129(6):699-707. PubMed
  12. Sooriakumaran P, Wilson C, Rombach I, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2022;130(1):43-53. PubMed
  13. Dai B, Zhang S, Wan FN, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial. Eur Urol Oncol. 2022;5(5):519-525. PubMed
  14. Ranasinghe W, Chapin BF, Kim IY, et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125(6):792-800. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides